Reviva Pharmaceuticals (RVPH) KOL Event summary

Introduction and agenda

• Webinar focused on phase III RECOVER trial results for brilaroxazine in schizophrenia, including trial outcomes, vocal biomarker analysis, and Q&A.

• Overview of R&D pipeline, including brilaroxazine's development for neuropsychiatric and inflammatory conditions.

• The event featured Dr. Mark Opler and Dr. Brian Kirkpatrick, both leading experts in psychiatric research and schizophrenia.

• Agenda included review of efficacy, safety, and new biomarker data.

Market insights and analysis

• Schizophrenia affects 1.1% of the global population, with 30% of patients treatment-refractory and significant unmet needs in negative symptoms and adherence.

• Current therapies have suboptimal efficacy, poor tolerability, and high discontinuation rates.

• The estimated market opportunity for schizophrenia treatments is $13.4B by 2032.

• Brilaroxazine may address unmet needs, including negative symptoms and treatment adherence.

Investment thesis and rationale

• Brilaroxazine demonstrated robust efficacy across primary and secondary endpoints, including positive, negative, cognitive, and social functioning, in phase II and III trials.

• Consistent results across US and international populations, with effect sizes comparable or superior to leading antipsychotics.

• Potential for broad-spectrum efficacy and improved adherence due to favorable side effect profile.

• Regulatory discussions are ongoing, with a planned NDA submission in Q1 2026.